Testing adebrelimab plus chemo before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy, with or without another drug (bevacizumab), given before surgery for people with a certain type of lung cancer. The goal is to see if this combination helps shrink the tumor and makes surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a certain type of lung cancer called non-squamous non-small cell lung cancer that can be removed with surgery.
- You are between 18 and 65 years old.
- You have not had any previous treatment for this cancer, like surgery, chemotherapy, or immunotherapy.
- You are in good enough health to be active (ECOG score 0 or 1) and your lungs are working well enough for surgery.
- You are not allergic to any of the study drugs or chemotherapy medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This trial tests whether adding adebrelimab (an immunotherapy drug) to standard chemotherapy before surgery can shrink non-small cell lung cancer that can be removed. The goal is to improve the chance of successful surgery and reduce the risk of the cancer coming back.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery can shrink tumors better in lung cancer that has certain genetic changes. The hope is that this pre-surgery treatment will improve outcomes.
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
Hear when a new Resectable Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.